Medications for Advanced Melanoma
As part of our commitment to resident education, Cutis is excited to offer this monthly section with board-relevant, easy-to-review material.
This fact sheet provides a list of the current US Food and Drug Administration approved medications for treatment of metastatic melanoma, and describes their mechanism of action and any related cutaneous side effects.
Practice Question Answers
1. Which of the following medications is considered an MEK inhibitor?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
3. What medication can be administered as a subcutaneous injection?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
5. Which of the following medications is an IL-2 cytokine?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
